+ Follow IMATINIB Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1344307
[Title] => Access program helps poor cancer patients get treatment
[Summary] => A patient support group has lauded Novartis Healthcare Philippines for its unprecedented access program that helps underprivileged patients get the cancer treatments they need.
[DatePublished] => 2014-07-10 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] => http://media.philstar.com/images/the-philippine-star/business/science-and-technology/20140710/Max-Philippines-Novartis-Healthcare.jpg
)
[1] => Array
(
[ArticleID] => 931772
[Title] => Novartis celebrates a decade of helping Filipino cancer patients
[Summary] => More than 500 cancer patients, their families and caregivers recently gathered at Camp Aguinaldo in Quezon City to celebrate the 10th anniversary of the Novartis Oncology Access (NOA) program.
[DatePublished] => 2013-04-18 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 580426
[Title] => Novartis to continue helping poor patients
[Summary] => Novartis Healthcare Phils. has reaffirmed its commitment to implement innovative programs designed to help underprivileged Filipino patients gain access to effective cancer treatments.
[DatePublished] => 2010-06-03 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 464588
[Title] => Reducing risk of cancer returning in patients
[Summary] => MANILA, Philippines – Data published in the online edition of the Lancet show that imatinib, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.
[DatePublished] => 2009-05-07 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
IMATINIB
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1344307
[Title] => Access program helps poor cancer patients get treatment
[Summary] => A patient support group has lauded Novartis Healthcare Philippines for its unprecedented access program that helps underprivileged patients get the cancer treatments they need.
[DatePublished] => 2014-07-10 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] => http://media.philstar.com/images/the-philippine-star/business/science-and-technology/20140710/Max-Philippines-Novartis-Healthcare.jpg
)
[1] => Array
(
[ArticleID] => 931772
[Title] => Novartis celebrates a decade of helping Filipino cancer patients
[Summary] => More than 500 cancer patients, their families and caregivers recently gathered at Camp Aguinaldo in Quezon City to celebrate the 10th anniversary of the Novartis Oncology Access (NOA) program.
[DatePublished] => 2013-04-18 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 580426
[Title] => Novartis to continue helping poor patients
[Summary] => Novartis Healthcare Phils. has reaffirmed its commitment to implement innovative programs designed to help underprivileged Filipino patients gain access to effective cancer treatments.
[DatePublished] => 2010-06-03 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 464588
[Title] => Reducing risk of cancer returning in patients
[Summary] => MANILA, Philippines – Data published in the online edition of the Lancet show that imatinib, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.
[DatePublished] => 2009-05-07 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest